 David Kao
Concepts (340)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 30 | 2022 | 2029 | 5.260 |
Why?
| | Stroke Volume | 16 | 2022 | 551 | 2.310 |
Why?
| | Machine Learning | 5 | 2022 | 271 | 2.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 69 | 1.780 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 359 | 1.710 |
Why?
| | Methadone | 4 | 2016 | 76 | 1.670 |
Why?
| | Cardiomyopathies | 5 | 2022 | 309 | 1.650 |
Why?
| | Electronic Health Records | 6 | 2022 | 724 | 1.170 |
Why?
| | Propanolamines | 3 | 2019 | 107 | 1.060 |
Why?
| | Arrhythmias, Cardiac | 4 | 2016 | 328 | 1.040 |
Why?
| | Cardiomyopathy, Dilated | 7 | 2017 | 356 | 0.970 |
Why?
| | Buprenorphine | 2 | 2016 | 106 | 0.960 |
Why?
| | Telemedicine | 3 | 2020 | 595 | 0.890 |
Why?
| | Torsades de Pointes | 4 | 2016 | 33 | 0.880 |
Why?
| | Pulmonary Edema | 1 | 2021 | 148 | 0.840 |
Why?
| | Coffee | 1 | 2021 | 13 | 0.840 |
Why?
| | Stroke | 2 | 2021 | 992 | 0.810 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 50 | 0.810 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 69 | 0.730 |
Why?
| | Mobile Applications | 1 | 2021 | 147 | 0.730 |
Why?
| | Prosthesis Failure | 1 | 2020 | 119 | 0.730 |
Why?
| | Device Removal | 1 | 2020 | 120 | 0.720 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 111 | 0.720 |
Why?
| | Spironolactone | 1 | 2019 | 38 | 0.720 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 58 | 0.710 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 408 | 0.700 |
Why?
| | Long QT Syndrome | 3 | 2016 | 87 | 0.700 |
Why?
| | Medical Records | 2 | 2019 | 175 | 0.690 |
Why?
| | Mortality | 3 | 2019 | 317 | 0.680 |
Why?
| | Artificial Intelligence | 1 | 2019 | 130 | 0.680 |
Why?
| | Humans | 72 | 2022 | 117633 | 0.680 |
Why?
| | Coronary Disease | 1 | 2021 | 408 | 0.670 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 32 | 0.660 |
Why?
| | Periodicals as Topic | 1 | 2020 | 233 | 0.640 |
Why?
| | United States | 19 | 2021 | 12768 | 0.630 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 54 | 0.620 |
Why?
| | Aged | 27 | 2022 | 20249 | 0.620 |
Why?
| | Hospital Records | 1 | 2016 | 13 | 0.610 |
Why?
| | Proteoglycans | 1 | 2017 | 100 | 0.600 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 395 | 0.590 |
Why?
| | Risk Assessment | 7 | 2020 | 3208 | 0.590 |
Why?
| | Hospitalization | 9 | 2021 | 1774 | 0.580 |
Why?
| | Survival | 1 | 2015 | 39 | 0.570 |
Why?
| | Tetrazoles | 1 | 2015 | 29 | 0.570 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 53 | 0.560 |
Why?
| | Disease Management | 1 | 2020 | 603 | 0.560 |
Why?
| | Female | 43 | 2022 | 63247 | 0.550 |
Why?
| | Retrospective Studies | 19 | 2022 | 12331 | 0.540 |
Why?
| | Decision Support Systems, Clinical | 4 | 2020 | 162 | 0.530 |
Why?
| | Research Design | 1 | 2020 | 968 | 0.520 |
Why?
| | Biomedical Research | 1 | 2020 | 598 | 0.520 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1152 | 0.520 |
Why?
| | Registries | 2 | 2020 | 1969 | 0.490 |
Why?
| | United States Food and Drug Administration | 4 | 2016 | 185 | 0.490 |
Why?
| | Middle Aged | 25 | 2021 | 28659 | 0.490 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 1777 | 0.480 |
Why?
| | Diet | 1 | 2021 | 1115 | 0.480 |
Why?
| | Muscle Proteins | 1 | 2015 | 226 | 0.480 |
Why?
| | Myocardium | 3 | 2017 | 1001 | 0.470 |
Why?
| | Quality Improvement | 2 | 2020 | 940 | 0.470 |
Why?
| | Legislation, Medical | 1 | 2012 | 13 | 0.460 |
Why?
| | Peripartum Period | 4 | 2022 | 9 | 0.460 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 188 | 0.460 |
Why?
| | Male | 35 | 2022 | 60403 | 0.460 |
Why?
| | Amiodarone | 1 | 2012 | 24 | 0.460 |
Why?
| | Pharmacogenetics | 4 | 2021 | 139 | 0.460 |
Why?
| | Adult | 26 | 2022 | 32118 | 0.440 |
Why?
| | Patient Readmission | 1 | 2018 | 659 | 0.440 |
Why?
| | Pyrazines | 2 | 2008 | 74 | 0.420 |
Why?
| | Postoperative Complications | 2 | 2020 | 2113 | 0.420 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 155 | 0.420 |
Why?
| | Catheter Ablation | 1 | 2015 | 343 | 0.420 |
Why?
| | Heart Arrest | 4 | 2019 | 327 | 0.410 |
Why?
| | Hospital Mortality | 5 | 2022 | 853 | 0.400 |
Why?
| | Triazoles | 2 | 2008 | 135 | 0.400 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 470 | 0.400 |
Why?
| | Treatment Outcome | 9 | 2021 | 9353 | 0.400 |
Why?
| | Transfusion Reaction | 1 | 2011 | 81 | 0.390 |
Why?
| | Databases, Factual | 5 | 2020 | 1145 | 0.390 |
Why?
| | Patient Transfer | 1 | 2012 | 161 | 0.390 |
Why?
| | Insurance, Health | 1 | 2012 | 265 | 0.380 |
Why?
| | Patient Discharge | 2 | 2021 | 820 | 0.380 |
Why?
| | Ventricular Function, Left | 4 | 2022 | 503 | 0.380 |
Why?
| | Anemia | 1 | 2011 | 164 | 0.370 |
Why?
| | Renal Insufficiency | 1 | 2011 | 133 | 0.360 |
Why?
| | Marketing | 1 | 2008 | 24 | 0.360 |
Why?
| | Thiazolidinediones | 1 | 2010 | 156 | 0.350 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 21 | 0.350 |
Why?
| | Risk Factors | 8 | 2020 | 9124 | 0.350 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 46 | 0.340 |
Why?
| | Simvastatin | 1 | 2008 | 70 | 0.340 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 58 | 0.330 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 22 | 0.330 |
Why?
| | Heart Ventricles | 4 | 2017 | 756 | 0.330 |
Why?
| | Drug Industry | 1 | 2008 | 105 | 0.320 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 233 | 0.320 |
Why?
| | Electrocardiography | 4 | 2019 | 650 | 0.320 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1199 | 0.320 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 896 | 0.320 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2013 | 70 | 0.320 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1228 | 0.310 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 1717 | 0.310 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 146 | 0.300 |
Why?
| | Precision Medicine | 5 | 2022 | 291 | 0.300 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1819 | 0.300 |
Why?
| | Ventricular Remodeling | 2 | 2017 | 216 | 0.280 |
Why?
| | Cause of Death | 2 | 2019 | 399 | 0.280 |
Why?
| | Phenotype | 3 | 2020 | 2875 | 0.270 |
Why?
| | Pandemics | 3 | 2022 | 1155 | 0.270 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2527 | 0.270 |
Why?
| | Pregnancy | 6 | 2022 | 5554 | 0.270 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 643 | 0.270 |
Why?
| | Young Adult | 9 | 2022 | 11077 | 0.270 |
Why?
| | Glucose | 1 | 2010 | 926 | 0.270 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 397 | 0.260 |
Why?
| | Incidence | 4 | 2021 | 2504 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1209 | 0.260 |
Why?
| | Adolescent | 10 | 2020 | 18902 | 0.250 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6795 | 0.250 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 721 | 0.240 |
Why?
| | Sex Factors | 3 | 2019 | 1918 | 0.240 |
Why?
| | Biological Specimen Banks | 2 | 2022 | 65 | 0.240 |
Why?
| | Medicare | 2 | 2020 | 720 | 0.230 |
Why?
| | Prognosis | 5 | 2020 | 3549 | 0.230 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1026 | 0.220 |
Why?
| | Insulin Resistance | 1 | 2010 | 1163 | 0.210 |
Why?
| | Red Meat | 1 | 2021 | 5 | 0.210 |
Why?
| | Smartphone | 1 | 2021 | 65 | 0.210 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 31 | 0.210 |
Why?
| | Losartan | 1 | 2020 | 15 | 0.210 |
Why?
| | Lisinopril | 1 | 2020 | 18 | 0.210 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 22 | 0.210 |
Why?
| | Referral and Consultation | 2 | 2017 | 671 | 0.210 |
Why?
| | Speech | 1 | 2021 | 84 | 0.210 |
Why?
| | Hypertension | 2 | 2020 | 1202 | 0.200 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 337 | 0.200 |
Why?
| | Angioedema | 1 | 2020 | 18 | 0.200 |
Why?
| | Turner Syndrome | 1 | 2021 | 41 | 0.200 |
Why?
| | Protective Factors | 1 | 2021 | 96 | 0.200 |
Why?
| | Software | 2 | 2015 | 532 | 0.200 |
Why?
| | Time Factors | 3 | 2020 | 6906 | 0.200 |
Why?
| | American Heart Association | 2 | 2019 | 305 | 0.200 |
Why?
| | Data Accuracy | 1 | 2020 | 49 | 0.200 |
Why?
| | Actigraphy | 1 | 2021 | 126 | 0.200 |
Why?
| | Social Determinants of Health | 1 | 2022 | 122 | 0.200 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 64 | 0.200 |
Why?
| | Bionics | 1 | 2019 | 9 | 0.190 |
Why?
| | California | 2 | 2012 | 386 | 0.190 |
Why?
| | Milk | 1 | 2021 | 140 | 0.190 |
Why?
| | Medical Futility | 1 | 2019 | 25 | 0.190 |
Why?
| | Editorial Policies | 1 | 2020 | 53 | 0.190 |
Why?
| | Medical Informatics | 1 | 2020 | 98 | 0.190 |
Why?
| | Medical Record Linkage | 1 | 2020 | 53 | 0.190 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 120 | 0.180 |
Why?
| | Prescription Drugs | 1 | 2020 | 114 | 0.180 |
Why?
| | Echocardiography | 2 | 2019 | 616 | 0.180 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 28 | 0.180 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 41 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2021 | 264 | 0.180 |
Why?
| | Cohort Studies | 3 | 2021 | 5112 | 0.170 |
Why?
| | Tobacco Use | 1 | 2019 | 59 | 0.170 |
Why?
| | Genotype | 2 | 2021 | 1825 | 0.170 |
Why?
| | Child Health Services | 1 | 2020 | 183 | 0.170 |
Why?
| | Computer Graphics | 2 | 2015 | 48 | 0.170 |
Why?
| | Cluster Analysis | 1 | 2019 | 476 | 0.170 |
Why?
| | Florida | 1 | 2018 | 74 | 0.170 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 9 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2106 | 0.170 |
Why?
| | Advisory Committees | 1 | 2019 | 220 | 0.170 |
Why?
| | Prospective Studies | 4 | 2021 | 6422 | 0.160 |
Why?
| | Length of Stay | 3 | 2021 | 1046 | 0.160 |
Why?
| | Forecasting | 1 | 2019 | 371 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2019 | 158 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C19 | 3 | 2022 | 21 | 0.160 |
Why?
| | Academic Medical Centers | 1 | 2020 | 414 | 0.160 |
Why?
| | Consensus | 1 | 2019 | 507 | 0.160 |
Why?
| | Pressure Ulcer | 1 | 2017 | 26 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4911 | 0.160 |
Why?
| | Patient Participation | 1 | 2020 | 362 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 455 | 0.150 |
Why?
| | Nursing Assessment | 1 | 2017 | 67 | 0.150 |
Why?
| | Tilidine | 1 | 2016 | 3 | 0.150 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 109 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 449 | 0.150 |
Why?
| | Heart Diseases | 1 | 2020 | 367 | 0.150 |
Why?
| | Computational Biology | 2 | 2017 | 481 | 0.150 |
Why?
| | Databases, Genetic | 1 | 2017 | 177 | 0.150 |
Why?
| | Cardiology | 1 | 2019 | 339 | 0.140 |
Why?
| | Oxycodone | 1 | 2016 | 48 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 349 | 0.140 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 4 | 0.140 |
Why?
| | Rheumatic Fever | 1 | 2015 | 8 | 0.140 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 19 | 0.140 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 38 | 0.140 |
Why?
| | Naloxone | 1 | 2016 | 113 | 0.140 |
Why?
| | Sex Distribution | 1 | 2016 | 390 | 0.140 |
Why?
| | Marijuana Use | 1 | 2018 | 157 | 0.140 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 27 | 0.140 |
Why?
| | Angiotensin II | 1 | 2015 | 111 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1595 | 0.140 |
Why?
| | Mothers | 1 | 2020 | 664 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 48 | 0.130 |
Why?
| | United Kingdom | 1 | 2015 | 245 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 770 | 0.130 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 150 | 0.130 |
Why?
| | International Classification of Diseases | 1 | 2015 | 130 | 0.130 |
Why?
| | Heart Rate | 2 | 2022 | 788 | 0.130 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 530 | 0.130 |
Why?
| | Age Factors | 2 | 2019 | 3223 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1650 | 0.120 |
Why?
| | Chronic Disease | 2 | 2020 | 1674 | 0.120 |
Why?
| | Gene Regulatory Networks | 1 | 2015 | 220 | 0.120 |
Why?
| | Cholesterol | 1 | 2015 | 391 | 0.120 |
Why?
| | MicroRNAs | 2 | 2017 | 631 | 0.120 |
Why?
| | Gene Expression | 2 | 2017 | 1520 | 0.120 |
Why?
| | Down-Regulation | 1 | 2015 | 648 | 0.120 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 80 | 0.120 |
Why?
| | Federal Government | 1 | 2012 | 30 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 398 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 698 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 502 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2017 | 2757 | 0.110 |
Why?
| | Drug Resistance | 1 | 2012 | 182 | 0.110 |
Why?
| | Area Under Curve | 1 | 2012 | 314 | 0.110 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 109 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1971 | 0.110 |
Why?
| | Patient Safety | 1 | 2015 | 310 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2206 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 191 | 0.100 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 352 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3574 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2012 | 305 | 0.100 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1036 | 0.100 |
Why?
| | Survival Rate | 1 | 2015 | 1807 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2012 | 1695 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 963 | 0.100 |
Why?
| | Managed Care Programs | 2 | 2022 | 159 | 0.100 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 201 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2017 | 814 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1419 | 0.090 |
Why?
| | Emergency Medical Services | 1 | 2015 | 541 | 0.090 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 32 | 0.090 |
Why?
| | Primary Health Care | 1 | 2019 | 1573 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1584 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2884 | 0.090 |
Why?
| | Drug Approval | 1 | 2008 | 80 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 2010 | 335 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2007 | 161 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 2018 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 357 | 0.080 |
Why?
| | Colorado | 3 | 2022 | 4401 | 0.070 |
Why?
| | Zimbabwe | 2 | 2017 | 47 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 234 | 0.070 |
Why?
| | Analgesics, Opioid | 1 | 2013 | 759 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1012 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3269 | 0.070 |
Why?
| | Depression | 2 | 2022 | 1196 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4630 | 0.070 |
Why?
| | Models, Biological | 1 | 2012 | 1763 | 0.070 |
Why?
| | Psychological Tests | 1 | 2005 | 135 | 0.070 |
Why?
| | Mandible | 1 | 2004 | 59 | 0.070 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 43 | 0.060 |
Why?
| | Animals | 2 | 2021 | 34350 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 780 | 0.060 |
Why?
| | Child | 5 | 2020 | 18649 | 0.060 |
Why?
| | Algorithms | 3 | 2020 | 1550 | 0.060 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 44 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 84 | 0.060 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 123 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 4 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 178 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 220 | 0.050 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 8 | 0.050 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 24 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2022 | 203 | 0.050 |
Why?
| | Health Services Misuse | 1 | 2020 | 39 | 0.050 |
Why?
| | Morbidity | 1 | 2020 | 262 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 453 | 0.050 |
Why?
| | Antigens, CD | 1 | 2002 | 470 | 0.050 |
Why?
| | Grounded Theory | 1 | 2019 | 26 | 0.050 |
Why?
| | Metoprolol | 1 | 2019 | 43 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2016 | 0.050 |
Why?
| | Aftercare | 1 | 2020 | 191 | 0.040 |
Why?
| | Bias | 1 | 2020 | 199 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2512 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 244 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 334 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 359 | 0.040 |
Why?
| | Focus Groups | 1 | 2019 | 376 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 617 | 0.040 |
Why?
| | Neoplasms | 1 | 2010 | 2139 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 100 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2016 | 15 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1163 | 0.040 |
Why?
| | Frail Elderly | 1 | 2017 | 103 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 175 | 0.040 |
Why?
| | Puerperal Disorders | 1 | 2016 | 33 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 351 | 0.040 |
Why?
| | World Health Organization | 1 | 2016 | 112 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 506 | 0.040 |
Why?
| | Drug Combinations | 1 | 2016 | 303 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 88 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 85 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1680 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1070 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2948 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 1021 | 0.030 |
Why?
| | Mass Screening | 2 | 2013 | 1081 | 0.030 |
Why?
| | Infant | 2 | 2015 | 8255 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 566 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 9714 | 0.030 |
Why?
| | Anthracyclines | 1 | 2010 | 39 | 0.030 |
Why?
| | Trastuzumab | 1 | 2010 | 95 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 85 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 999 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 226 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 870 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 226 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 103 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2573 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 393 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 651 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 472 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 784 | 0.020 |
Why?
| | Dentists | 1 | 2004 | 18 | 0.020 |
Why?
| | Hospitals, University | 1 | 2005 | 189 | 0.020 |
Why?
| | Femur Neck | 1 | 2004 | 61 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 61 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1267 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 251 | 0.020 |
Why?
| | Nurses | 1 | 2005 | 129 | 0.020 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 23 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1451 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 432 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 613 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1261 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 948 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2106 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 771 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2898 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|